Lung Cancer

A clinical trial has started to evaluate the investigational drug MK-1084 and Keytruda among some patients with metastatic non-small cell lung cancer.

During cancer, we all share a common denominator: hope.

Since January 2024, the Food and Drug Administration has approved several treatments and combinations for solid tumors.

Dendritic cell maturation agent plinabulin, immunotherapy and chemotherapy are being studied in first-line extensive-stage small cell lung cancer.

Throughout my life, taking walks helped a lot with easing anxiety, so walking helped me when I received two diagnoses of cancer.

Certain patients with lung cancer who have EGFR exon 20 insertion mutations may have a new treatment option, which welcomes a new “milestone.”

As a three-time cancer survivor, I wonder: are my roots damaged or resting to find their way?

After having early-stage breast cancer and stage 3B lung cancer, I'm choosing to give back. Here's how.

The CURE® 2024 Lung Cancer Special Issue provides insight into the ever-changing innovation in the lung cancer space.

This special issue of CURE Lung Cancer takes a deeper dive into ALK-positive non-small cell lung cancer.

Patients with small cell lung cancer have reasons to be optimistic these days, as one expert explains to CURE.

What advancements for ALK-positive non-small cell lung cancer are on the way, from treating earlier stages of disease to postsurgical options?

The Food and Drug Administration approved Rybrevant plus carboplatin and pemetrexed for locally advanced or metastatic non-small cell lung cancer (NSCLC) that has EGFR exon 20 insertion mutations.

I agree that cancer is portrayed very stereotypically in society, so here are some ways I think we can highlight the reality of cancer.

After Tepmetko’s full approval for metastatic lung cancer treatment, patients should feel that the data from the accelerated approval is validated, an expert said.

The FDA granted a breakthrough therapy designation to BAY 2927088 after it showed promise in treating patients with HER2 mutations.

From Ben Lanzarone of “Happy Days” and “Grease” dying of lung cancer to “Good Morning America’s” Michael Strahan providing an update on his daughter’s medulloblastoma treatment, here’s what’s happening in the oncology space this week.

A recent experience has emphasized to me that we should live life to its fullest every single day.

The Food and Drug Administration is reviewing Dato-DXd for potential approval to treat pretreated advanced nonsquamous non-small cell lung cancer.

Personalized cancer vaccines are on the horizon and could be available for some patient populations as soon as next year, one expert said.

An immunotherapy-targeted therapy combination could offer a new treatment option to patients with non-small cell lung cancer whose tumors have become resistant to other treatments.

The Food and Drug Administration has approved Tagrisso plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.

The Food and Drug Administration approved Tepmetko for adults with metastatic non-small cell lung cancer with MET exon 14 skipping alterations.

The Food and Drug Administration will review Augtyro for potential approval in children and adults with advanced solid cancers that harbor NTRK gene fusions.

Researchers have initiated a phase 2 trial assessing a novel tyrosine kinase inhibitor that can potentially penetrate the central nervous system in patients with ALK-positive non-small cell lung cancer and other solid tumors.

At a cancer support group at my church, we sit together and share our cancer stories.

Treatment with Opdivo (nivolumab) and chemotherapy did not significantly improve progression-free survival when compared with chemotherapy alone among some patients with EGFR-mutated metastatic non-small-cell lung cancer.

Treatment with Tagrisso after chemoradiation resulted in patients with EGFR-mutant stage 3 non-small cell lung cancer being nearly three times less likely to experience disease progression when compared with those treated with Imfinzi or subject to observation.

The development of immune-related side effects is associated with improved overall survival among patients with metastatic non-small cell lung cancer (NSCLC) who receive immune checkpoint inhibitor therapy.

The FDA has granted Priority Review to oral ALK inhibitor Alecensa (alectinib) for patients with early-stage ALK-positive non-small cell lung cancer.